Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 2/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.32 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.31 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.31 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.31 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.31 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.31 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.31 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22185896 | 0.88 | RXRA (0.31) | RXRAGRIN1GRIN2B | |
| SCHEMBL22199104 | 0.83 | NR2E1 (0.38) | KCNH2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL22199078 | 0.70 | APP (0.39) | KCNH2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL22199006 | 0.64 | ALDH1A1 (0.32) | — | |
| SCHEMBL10160988 | 0.61 | GRM5 (0.33) | — | |
| SCHEMBL22185963 | 0.60 | PDE2A (0.31) | — | |
| SCHEMBL20390081 | 0.60 | KDM4E (0.39) | GRIN1GRIN2B | |
| SCHEMBL22184938 | 0.60 | KCNH2 (0.42) | KCNH2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL11974045 | 0.60 | CPB2 (0.48) | — | |
| SCHEMBL22199103 | 0.59 | SCD (0.39) | KCNH2PSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200206233-A1 | HETEROCYCLIC COMPOUNDS AS MUTANT IDH INHIBITORS | INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) | 2020-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200206233-A1 | HETEROCYCLIC COMPOUNDS AS MUTANT IDH INHIBITORS | IDH1, IDH2, IDH3A | RXRA 4608/4885GRIN1 2054/4885GRIN2B 2263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.